Literature DB >> 15794384

Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.

Christian Enzinger1, Siegrid Strasser-Fuchs, Stefan Ropele, Peter Kapeller, Reinhold Kleinert, Franz Fazekas.   

Abstract

In rare instances, demyelinating disorders present with radiological features that mimic a brain tumour. This often leads to biopsy, which--apart from carrying significant morbidity--frequently turns out as nondiagnostic or dispensable. We therefore set out to assess the contribution of repeated conventional magnetic resonance imaging (MRI), 1H-MR spectroscopy and magnetization transfer imaging in establishing a correct diagnosis of tumefactive demyelinating lesions (TDLs). We studied two females and one male, who presented with TDLs that led to brain biopsy in two cases, for up to three years. TDLs were characterized by the following features: (a) delayed or absent response to high-dose steroids together with progressive lesion growth over several weeks; (b) late or sparse enhancement, ill-defined borders, signal inhomogeneity and considerable concomitant oedema; and (c) normalization of initial increases in lipid and lactate peaks within three to four weeks, followed by persistent, marked reductions of the neuronal marker NAA and MTR values around or below 30%. These imaging characteristics reflected the histological correlate of marked demyelination in the absence of significant inflammation. MRI techniques thus appear to have the potential to establish a correct diagnosis of this subtype of TDLs. Awareness of these possibilities might obviate the need for biopsy at least in some cases in future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794384     DOI: 10.1191/1352458505ms1145oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain : A review of reported findings.

Authors:  A Seewann; C Enzinger; M Filippi; F Barkhof; A Rovira; A Gass; D Miller; X Montalban; A Thompson; T Yousry; M Tintore; N de Stefano; J Palace; M Rovaris; C Polman; F Fazekas
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 4.849

3.  Acute multiple sclerosis lesion pathology does not predict subsequent clinical course-a biopsy study.

Authors:  Hugh Kearney; Tucker Price; Jane Cryan; Alan Beausang; Seamus Looby; Francesca M Brett; Michael Farrell
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

4.  Cerebral tumefactive demyelinating lesions.

Authors:  Wei Qi; G E Jia; Xinsheng Wang; Maozhi Zhang; Zhenyu Ma
Journal:  Oncol Lett       Date:  2015-07-10       Impact factor: 2.967

5.  Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis.

Authors:  Mirja Wallner-Blazek; Alex Rovira; Massimo Fillipp; Mara A Rocca; David H Miller; Klaus Schmierer; Jette Frederiksen; Achim Gass; Hugo Gama; Charles P Tilbery; Antonio J Rocha; José Flores; Frederik Barkhof; Alexandra Seewann; Jacqueline Palace; Tarek Yousry; Xavier Montalban; Christian Enzinger; Franz Fazekas
Journal:  J Neurol       Date:  2013-04-26       Impact factor: 4.849

Review 6.  The next generation of positron emission tomography radiopharmaceuticals in oncology.

Authors:  Samuel L Rice; Celeste A Roney; Pierre Daumar; Jason S Lewis
Journal:  Semin Nucl Med       Date:  2011-07       Impact factor: 4.446

Review 7.  Tumefactive demyelinating lesions: nine cases and a review of the literature.

Authors:  Lei Xia; Song Lin; Zhong-cheng Wang; Shao-wu Li; Li Xu; Jing Wu; Shu-yu Hao; Chuan-chuan Gao
Journal:  Neurosurg Rev       Date:  2009-01-27       Impact factor: 3.042

8.  Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.

Authors:  Marc C Mabray; Benjamin A Cohen; Javier E Villanueva-Meyer; Francisco E Valles; Ramon F Barajas; James L Rubenstein; Soonmee Cha
Journal:  AJR Am J Roentgenol       Date:  2015-11       Impact factor: 3.959

9.  Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.

Authors:  Xuling Lin; Wai-Yung Yu; Lishya Liauw; Russell Jude Chander; Weiling E Soon; Hwei Yee Lee; Kevin Tan
Journal:  Neurol Clin Pract       Date:  2017-02

10.  Pitfalls in the diagnosis of a tumefactive demyelinating lesion: A case report.

Authors:  Maria Gavra; Efstathios Boviatsis; Lampis C Stavrinou; Damianos Sakas
Journal:  J Med Case Rep       Date:  2011-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.